Publication date: 03/09/2018
Shareholders approve new name which better reflects the Company's ambition to deliver best in class therapies for back of the eye disorders
ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing innovative treatments for back of the eye disorders, and with an innovative pipeline in diabetic eye disease, announces that all name change resolutions proposed at an Extraordinary General Meeting ("EGM") held today Monday September 3, 2018, gained shareholder approval. As a result, ThromboGenics NV will become "Oxurion NV".
The name change will be implemented in the next days and weeks. The Company stock ticker symbol will also change from "THR" to "OXUR".
The new corporate website will be www.oxurion.com .
Patrik De Haes, MD, CEO of ThromboGenics, comments: "The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders. The renaming comes at a moment when we have delivered important clinical milestones and are accelerating the development of our unique pipeline of disease modifying compounds for diabetic eye disease. Moreover, we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options."
"The new Oxurion logo, combined with the tagline 'Advancing science. Enhancing vision.' has been designed to convey the company's technological and scientific core, by linking our current strength and vision with our exciting future ambition.", he concludes.
ThromboGenics is a biopharmaceutical company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
ThromboGenics' clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME), which is in an ongoing Phase 2 clinical study in combination with Lucentis®, and THR-149, a plasma kallikrein inhibitor which is in a Phase 1 clinical study for DME. THR-687 (an integrin antagonist) is in late-stage preclinical development for the treatment of diabetic retinopathy and DME. THR-687 is expected to enter the clinic in Q3 2018. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.
ThromboGenics owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (outside the US).
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com